KoSyne NeuroTech Completes Series A Financing: Full-Stack Brain-Computer Neuromodulation Platform Leads a New Paradigm in Mental Disorder Diagnosis and Treatment

Recently, KoSyne NeuroTech, a company focused on next-generation brain-computer interface neuromodulation technologies, announced the completion of its Series A financing round.

This round was led by Oriental Fortune Capital, with participation from Glory Ventures. Existing shareholders Dalton Venture and Yunqi Capital continued to increase their investments. Qifeng Capital served as the financial advisor. The raised funds will be primarily used for product research and development iteration, medical device regulatory registration and filing, and global expansion.

Hundreds of millions of people worldwide suffering from mental and cognitive disorders such as depression, anxiety disorders, obsessive-compulsive disorder (OCD), and Alzheimer's disease are waiting for a more effective, more precise, and more accessible treatment solution. The traditional "one-size-fits-all" approach to treatment is poised for rapid disruption. Yet, no company globally has established a full-stack ecosystem—from underlying technologies to clinical applications—within the multi-energy neuromodulation space.

KoSyne NeuroTech aims to confront this complexity head-on—rejecting standardized, uniform treatments. The company is dedicated to interpreting each unique brain map through precise brain-computer interface technologies, striving to provide the optimal solution and an exceptional product experience that exceeds expectations for every individual struggling with mental disorders.

Driven by a deep understanding of mental and cognitive disorders, KoSyne NeuroTech has firmly committed to engaging directly with clinical practice, seeking the optimal solution for each specific scenario. Based on this commitment, the company has developed a globally leading brain-computer interface neuromodulation architecture comprising a "whole-brain functional connectivity computing engine + robotic navigation + multimodal closed-loop neuromodulation." This architecture is underpinned by the "whole-brain functional connectivity computing engine" and "robotic navigation," integrating insights into multiple energy modalities including magnetic, ultrasound, and electrical stimulation to achieve full-chain intelligence encompassing signal sensing, target calculation, precise execution, and closed-loop modulation.

Built upon this globally unique architecture, KoSyne NeuroTech has developed its proprietary transcranial focused ultrasound, navigated transcranial magnetic stimulation (TMS) system, and closed-loop electrical stimulation as a flexible technology platform. This approach precisely eliminates unnecessary technical interference, retaining only the most efficient intervention pathways. This problem-solving-centric research foundation enables KoSyne NeuroTech to truly provide individualized, effective systemic solutions for patients suffering from different indications, and represents one of the company's core competitive moats.

In response to the significant clinical need, KoSyne NeuroTech has established a clear three-phase implementation pathway: driving validation of cutting-edge technologies through high-level scientific research collaborations, establishing medical standards through rigorous clinical evidence, and simultaneously pursuing the development of home-use therapeutic devices. The company has built a product portfolio encompassing in-hospital treatment for mental and cognitive disorders and home-based treatment for mood and sleep disorders.

Focused ultrasound can precisely reach deep brain nuclei, targeting key brain regions involved in emotion, cognition, and pain, such as the thalamus, amygdala, hippocampus, and anterior cingulate cortex. However, the attenuation and deflection of acoustic waves after passing through the skull have long been a global technical challenge. In the area of transcranial focused ultrasound systems, KoSyne NeuroTech is progressively launching its proprietary systems with 64 to 1024 channels. Using a built-in phase control engine, the system performs waveform correction based on each patient's unique cranial anatomical features, overcoming the challenges of energy attenuation and focal point deflection when ultrasound waves traverse the skull. This enables the device to achieve millimeter-level precision in reaching deep brain regions and allows dynamic adjustment of the focal point, successfully transforming what was once a research-grade acoustic experiment heavily reliant on manual expertise into a stable, safe, and routine clinical diagnostic and therapeutic modality.

Regarding the navigated transcranial magnetic stimulation (TMS) system, KoSyne NeuroTech's navigated TMS system is the company's first Class III medical device to enter the registration clinical stage, offering a novel and precise treatment option for patients with depression. This system has already initiated the highest-standard clinical validation in the field of neuromodulation in China. For the first time, four national mental health centers—Beijing Anding Hospital, Shanghai Mental Health Center, The Second Xiangya Hospital of Central South University, and West China Hospital of Sichuan University—have simultaneously begun clinical enrollment, demonstrating strong clinical demand and high recognition.

In the area of closed-loop electrical stimulation products, the team leverages temporal interference electrical stimulation technology. By completing the self-developed translation of complex physical model algorithms for deep electrical fields, precise targeting is achieved. Equipped with a module for real-time, independently operating electroencephalography (EEG) signal analysis, this enables a temporally and spatially precise closed-loop electrical stimulation intervention solution. KoSyne NeuroTech's closed-loop electrical stimulation product is poised to serve as a critical bridge from intensive in-hospital treatment to long-term out-of-hospital management, establishing a comprehensive, lifelong closed-loop management system for mental and cognitive disorders.

KoSyne NeuroTech was founded by an experienced interdisciplinary team whose core members cover the full spectrum of capabilities, including neuroscience, acoustic engineering, medical imaging, artificial intelligence, robotics, and medical device regulatory affairs. This team possesses deep academic expertise, extensive industry experience, and a global perspective, positioning it as a core force leading the transformation in the diagnosis and treatment of mental and cognitive disorders worldwide.

KoSyne NeuroTech has already established research and clinical collaboration networks with several renowned universities and top-tier medical institutions overseas. The company plans to simultaneously initiate FDA and CE registration, aiming to be among the first to introduce its clinically validated precision neuromodulation model to markets in North America, Europe, and Southeast Asia, thereby enabling Chinese-originated innovations to serve hundreds of millions of patients with mental and cognitive disorders globally.

KoSyne NeuroTech firmly believes that understanding and enhancing emotion and cognition represent a fundamental human need—and a core piece of the puzzle leading to general intelligence. With each product iteration, KoSyne NeuroTech advances toward the same mission: to decode emotion, understand cognitive changes, and ultimately establish a precise, warm, and sustainable modulatory link between brain function and machines, responding to humanity's enduring desire to understand and be understood through technological innovation.